R

REGENXBIO

Develops AAV gene delivery therapies

Associate Director - Rare Disease Product Marketing

Product MarketingConfirmed live in the last 24 hours
Full-timeRockville, MD, USA

About the Job

Requirements

  • A bachelor's degree is required.
  • At least 7 years of product marketing, brand management, marketing strategy, commercial insights, or related commercial experience within the biotechnology or pharmaceutical industry.
  • Experience supporting or leading product launch preparation and lifecycle activities, including customer segmentation, brand strategy, promotional material development and approval, and field enablement.
  • Strong understanding of drug development and commercialization processes.
  • Ability to integrate primary qualitative and quantitative research and secondary research into strategic recommendations, value propositions, and marketing tactics.
  • Experience developing content for healthcare professionals, caregivers, and payers, and working through promotional review and approval processes while maintaining scientific accuracy and compliance.
  • Experience collaborating cross-functionally with marketing, medical, market access, regulatory/legal, commercial operations, and field teams.
  • Strong analytical and problem-solving skills, organization, and ability to work in ambiguity.
  • Proficiency with Excel, PowerPoint, and relevant market research, customer, and analytics tools; ability to translate data into marketing implications.
  • Experience managing agencies, vendors, and external partners to deliver marketing and insights work on time and within budget.

Responsibilities

  • Lead the development and execution of integrated rare disease brand plans, including customer segmentation, positioning, messaging, and omnichannel tactics for healthcare professional, payer, caregiver, and field audiences.
  • Translate market research, competitive intelligence, and field feedback into recommendations that inform brand planning, launch readiness, value positioning, and marketing performance.
  • Develop and manage healthcare professional- and payer-facing promotional materials, including digital and field-facing tools, through the promotional review process to ensure strategic alignment, scientific accuracy, and timely execution.
  • Manage agency and vendor partnerships for market research, creative development, media, analytics, and other marketing services to ensure high-quality deliverables on time and within budget.
  • Lead annual operating planning and marketing budget management; prioritize initiatives, track spend, and coordinate promotional asset lifecycle updates to support evolving brand and launch needs.
  • Collaborate with Commercial, Medical, Market Access, Regulatory/Legal review, R&D, Corporate Affairs, and field teams to align brand strategy, customer engagement, advisory boards, peer-to-peer education, and congress initiatives.
  • Communicate actionable recommendations to senior stakeholders and partner with commercial training and field teams to support rollout and adoption of new materials and initiatives.
  • Travel up to 25% for medical congresses, conferences, and internal meetings.

Desired Qualifications

  • An advanced degree (MS, PhD, MBA, or PharmD) in life sciences, business, or a healthcare-related field is preferred.
  • Rare disease and/or Duchenne experience is preferred.
  • Experience in a rare disease, specialty, or gene therapy setting is preferred.
  • Rare disease experience is strongly preferred.

About the Company

REGENXBIO

Develops AAV gene delivery therapies

REGENXBIO focuses on gene therapy using its NAV Technology Platform, an adeno-associated virus (AAV) gene delivery system with exclusive rights to more than 100 AAV vectors. The company generates revenue by licensing its platform, collecting royalties, and engaging in collaborations, while also developing its own one-time gene therapies for retinal, rare, and neurodegenerative diseases. Key products in later-stage trials include ABBV-RGX-314 for wet AMD and diabetic retinopathy, RGX-202 for Duchenne muscular dystrophy, and RGX-121 for Hunter syndrome, with a goal to advance five new therapies to pivotal-stage or commercial status by 2025 and FDA review for RGX-121 targeted in early 2026. REGENXBIO differentiates itself by owning a broad AAV vector library and offering end-to-end capabilities—from research to manufacturing—alongside a diversified revenue model that includes royalties, collaborations, and milestones.

Company size
201-500
Company stage
IPO
Headquarters
Rockville, MD
Founded
2009

Recently Posted Jobs

Explore more opportunities at REGENXBIO

See more jobs